What is the translation of " COAGULATION FACTOR " in Romanian?

• factor de coagulare
• factorul de coagulare

Examples of using Coagulation factor in English and their translations into Romanian

Recombinant coagulation factor VIII(octocog alfa).
Factor de coagulare VIII recombinant(octocog alfa).

NovoSeven contains activated recombinant coagulation factor VII.
NovoSeven conţine factor de coagulare VII activat recombinant.

Recombinant Coagulation factor VIII, 250 IU/ vial.
Factor de coagulare VIII recombinant, 250 UI/ flacon.

The average retention rate of the main plasma coagulation factor≥80%.
Rata medie de retenție a principal de coagulare în plasmă factor≥80%.

Recombinant coagulation factor VIII(octocog alfa) Intravenous use.
Factor de coagulare VIII recombinant(octocog alfa) Administrare intravenoasă.

Pharmacotherapeutic group: antihaemorrhagics, blood coagulation factor VIII; ATC code.
Grupa farmacoterapeutică: antihemoragice, factor de coagulare VIII; codul ATC.

Coagulation factor VIII 1000 IU von Willebrand factor 2400 IU.
Factor de coagulare VIII 1000 UI factor von Willebrand 2400 UI.

The active substance is recombinant human coagulation factor VIII(simoctocog alfa).
Substanţa activă este factorul de coagulare VIII uman recombinant(simoctocog alfa).

Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary(CHO) cells.
Factorul de coagulare VIII uman este produs prin tehnologia ADN- ului recombinant în celule ovariene de hamster chinezesc(OHC).

If possible, determine the degree of activity of a coagulation factor VIII.
Dacă este posibil, se determină gradul de activitate al unui factor de coagulare VIII.

It is a vitamin K-dependent coagulation factor and is synthesised in the liver.
Este un factor de coagulare dependent de vitamina K şi se sintetizează la nivelul ficatului.

RIXUBIS contains the active substance nonacog gamma and is a coagulation factor IX product.
RIXUBIS conţine substanţa activă nonacog gama şi este un produs ce conţine factorul de coagulare.

Coagulation factor concentrates(activated or non-activated) or recombinant Factor VIIa may be taken into account.
Trebuie luate în considerare concentrate de factori de coagulare(activate sau neactivate) sau Factor VIIa recombinant.

Pharmacotherapeutic group: antihemorrhagics: blood coagulation factor VIII, ATC code B02BD02.
Grupa farmacoterapeutică: antihemoragice: factor de coagulare VIII, codul ATC: B02BD02.

Coagulation factor V, clotting factor VIII, α 2-macroglobulin, and C1-esterase inhibitor are only slightly reduced and normalise within 1 to 2 days.
Factorul de coagulare V, factorul de coagulare VIII, α2- macroglobulina şi inhibitorul de C1- esterază sunt numai uşor reduse şi se normalizează în decurs de 1 până la 2 zile.

Simultaneous use of NovoSeven and coagulation factor concentrates should be avoided.
Utilizarea concomitentă de NovoSeven şi concentrate de factori de coagulare trebuie evitată.

Coagulation tests may become unreliable following administration of suggested coagulation factor concentrates.
Testele de coagulare pot deveni nesigure după administrarea concentratelor de factori de coagulare sugerate.

The active substance is catridecacog* recombinant coagulation factor XIII: 2500 IU/3 ml, after reconstitution, corresponding to a concentration of 833 IU/ml.
Substanţa activă este catridecacog*(factorul de coagulare XIII recombinant: 2500 UI/3 ml), după reconstituire, corespunde la o concentraţie de 833 UI/ml.

KOGENATE Bayer 250 IU powder and solvent for solution for injection Recombinant coagulation factor VIII(octocog alfa).
KOGENATE Bayer 250 UI pulbere şi solvent pentru soluţie injectabilă Factor de coagulare VIII recombinant(octocog alfa).

Pharmacotherapeutic group: Antihaemorrhagics: Blood coagulation factors, von Willebrand factor and coagulation factor VIII in combination.
Grupa farmacoterapeutică: antihemoragice, factori de coagulare a sângelui, factorul von Willebrand şi factorul de coagulare VIII în asociere.

The risk of a potential interaction between NovoSeven and coagulation factor concentrates is unknown.
Riscul unei interacţiuni potenţiale între NovoSeven şi concentratele de factori de coagulare nu este cunoscut.

Patients treated with recombinant coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
Pacienţii trataţi cu factor de coagulare VIII recombinant vor fi monitorizaţi cu atenţie pentru determinarea dezvoltării inhibitorilor prin observaţii clinice şi teste de laborator corespunzătoare.

Pharmacotherapeutic group: antihemorrhagics, blood coagulation factor VIII, ATC code: not yet assigned.
Grupa farmacoterapeutică: antihemoragice, factor de coagulare sangvină VIII, codul ATC: B02BD02.

In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
În general, toţi pacienţii trataţi cu medicamente ce conţin factor de coagulare VIII trebuie monitorizaţi cu atenţie pentru depistarea apariţiei inhibitorilor, utilizând observaţiile clinice şi testele de laborator adecvate.

ReFacto AF contains the active substance moroctocog alfa, human coagulation factor VIII produced by recombinant DNA technology.
ReFacto AF conţine substanţa activă moroctocog alfa, factor de coagulare VIII uman, produs prin tehnologia ADN- ului recombinant.

Eptacog alfa(activated) is recombinant coagulation factor VIIa with a molecular mass of approximately 50,000 Dalton produced by genetic engineering from baby hamster kidney cells(BHK Cells).
Eptacog alfa(activat) este factorul de coagulare VIIa recombinant cu o masă moleculară de aproximativ 50000 daltoni produs prin inginerie genetică din celule de rinichi de pui de hamster(celule RPH).

Helixate NexGen 1000 IU powder for solution for injection Recombinant coagulation factor VIII(octocog alfa) Intravenous use.
Helixate NexGen 1000 UI pulbere pentru soluţie injectabilă Factor de coagulare VIII recombinant(octocog alfa) Administrare intravenoasă.

In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observation and laboratory test.
În general, toţi pacienţii trataţi cu medicamente care conţin factor de coagulare VIII trebuie monitorizaţi atent în vederea depistării formării de inhibitori prin observaţia clinică şi a testelor de laborator corespunzătoare.

NovoEight contains approximately 125 IU/ml of human coagulation factor VIII(rDNA), turoctocog alfa after reconstitution.
NovoEight conţine aproximativ 125 UI/ml de factor de coagulare VIII uman(ADNr), turoctocog alfa.

In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
În general, toți pacienţii trataţi cu medicamente cu factor de coagulare VIII recombinant vor fi monitorizaţi cu atenţie pentru determinarea dezvoltării inhibitorilor prin observaţii clinice şi teste de laborator corespunzătoare.